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ORIGINAL ARTICLE

Remission of Grave’s Disease After Oral Anti-Thyroid
Drug Treatment
Osama Ishtiaq, Sabiha Waseem, M. Naeemul Haque, Najmul Islam and Abdul Jabbar

ABSTRACT
Objective: To evaluate remission rate of anti-thyroid drug treatment in patients with Grave’s disease, and to study the
factors associated with remission.
Study Design: A cross sectional study.
Place and Duration of Study: The Endocrine Department of the Aga Khan University Hospital, Karachi from 1999
to 2000.
Methodology: Seventy four patients of Grave’s disease were recruited who were prescribed medical treatment. Graves’
disease was diagnosed in the presence of clinical and biochemical hyperthyroidism along with anti-microsomal (AMA) and
anti-thyroglobulin antibodies (ATA) and thyroid scan. These patients were prescribed oral anti-thyroid drugs using titration
regime and followed at 3, 6, 12 and 18 months. Patients were categorized into two groups: “remission group” and
“treatment failure group” and results were compared using a chi-square test, t-test and logistic regression model with
significance at p < 0.05.
Results: A majority of the patients were females (62.6%, n=46). During the follow-up period of 18 months, 41.9% patients
went into remission. Univariate analysis showed that the initial free T4 level was significantly different (p < 0.05) in patients
in remission and treatment failure groups. Multivariate analysis showed only initial free T4 level was a significant predictor
of outcome. Positive AMA patients (n=27) had higher treatment failure (odds ratio: 2.55: 95%, CI 0.69 – 9:31), although
the difference was not statistically significant (p = 0.13).
Conclusion: Remission rates with oral anti-thyroid agents is markedly high. Patients should be offered alternate treatment
options to those who do not enter remission during a period of 12-18 months of treatment, those who develop relapse, and
those who have aggressive disease on initial presentation.
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INTRODUCTION
Grave’s disease is the commonest form of hyperthyroidism affecting women 5-10 times more frequently
than men.1 There is auto-immunity against the thyroidstimulating hormone (TSH) receptor as the central
pathogenetic element. The disease may have a number
of clinical manifestations, the most common being
thyrotoxicosis caused by generation of TSH receptor
activating autoantibodies (Graves’ hype-rthyroidism).
There are three main methods of treatment of Grave’s
hyperthyroidism; radioactive iodine (RAI), oral antithyroid medication and surgery. Most physicians prefer
the first one in United States, while antithyroid drugs are
preferred in Europe.2-4
The two drugs in common use for the treatment of
Grave’s disease, are methimazole (MMI) and
propylthiouracil (PTU). They are both thionamides and
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exert their anti-thyroid effect by inhibition of thyroid
peroxidase catalysed synthesis of thyroid hormones.
Thereby, thyroid hormone secretion gradually
diminishes, and the patient becomes euthyroid.
Although thionamides are highly effective in controlling
hyperthyroidism, long term remission is obtained only in
30-50% of patients.5-7 Moreover, it has been proven
from different clinical studies, that radioactive iodine
treatment results in the cure of Grave’s hyperthyroidism
and is therefore now considered a preferred treatment.8
Considering the fact that thionamides have a high
chance of failure, most of the patients still prefer antithyroid drugs for the treatment of Grave’s hyperthyroidism, probably due to fear of radioactivity and
greater initial cost.
In developing countries, including Pakistan, physicians
treating Grave’s hyperthyroidism mostly use anti-thyroid
drugs, as the first line treatment. The relapse and
remission rates of this treatment have not been studied
so far in the local population. Therefore, this study was
carried out to evaluate remission rates in the patients of
Grave’s hyperthyroidism treated with thionamides, and
to study the factors associated with the remission in
these patients.
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METHODOLOGY
Seventy four adult patients of Grave’s hyperthyroidism
were recruited, over the period of 1999 and 2000, from
the Endocrinology Clinic at the Aga Khan University
Hospital, Karachi, Pakistan. These patients were given
thionamides as a medical treatment for Grave’s disease.
Carbimazole was used as a thionamide drug, which is
equivalent to Methimazole. Graves’ disease was defined
as the presence of clinical and biochemical
hyperthyroidism (elevated serum T4 or more specifically
free T4 concentration and undetectable TSH) with an
elevated diffuse thyroid uptake seen in 99mTcpertechnetate scan. If an uptake scan were not
available, the presence of biochemical hyperthyroidism
with 2 of the following was required: diffuse goiter,
significant titer of thyroid peroxidase or thyroglobulin
autoantibodies (a titer of 1:100 was considered
significant), or both, and the presence of thyroid
ophthalmopathy. Free T4, T4 and TSH were measured
by Chemiluminescence method on Immunolite®.
Thyroid autoantibodies were measured by a
microparticle enzyme immunoassay. Thyroid receptor
antibodies were not done because of unavailability of
the diagnostic assays. Eye disease was defined
according to the presence of eye signs in categories 26 of the NO SPECS classification.9
Patients were assessed by a staff endocrinologist at 3,
6, 12 and 18 months. The usual policy is to follow the
patients till 18 months for disease remission, otherwise
the patient is offered other modes of treatment. Patients
were prescribed a titration regime of thionamides
according to Abraham et al.,5 in which the dose of
thionamides was titrated according to the free T4 and
TSH. They were also educated about the side effects of
the medicine and were asked to get complete blood
picture with granulocyte count in case they develop fever
or sore-throat or skin rash. At each visit, patients were
examined for signs and symptoms of Grave’s disease
including goitre and eye signs and were asked about
any side effects. Patients were categorized into 2
groups; remission group, and treatment failure group.
Patients, who were advised to stop treatment after they
became euthyroid at 6, 12 and 18 months follow-up,
were placed in the remission group, while patients who
developed hyperthyroidism after stopping treatment at
anytime during the period of eighteen months were
termed as relapse and those whose treatment never
stopped, were placed in the treatment failure group. The
main outcome was the measurement of remission of
Grave’s disease with oral anti-thyroid medicines.
Patients of hyperthyroidism given radio active iodine or
having causes other than Grave’s disease and those
having malignant opthalmopathy, myopathy, cardiac
arrhythmia, heart failure, weight loss > 10%, pregnancy,
poor compliance and follow-up of less than 18 months,
were excluded.
Statistical tool used for data entry and evaluation was
SPSS 13.0. Association between categorical independent

variables (gender, palpable goiter, positive anti-thyroid
antibodies, eye signs, patients with age less or greater
than 40 years) and outcome was measured using chisquare and Fischer’s exact test while t-test was used for
quantitative independent variables (age, mean free T4,
dose of carbimazole). Multivariate analysis was done
using logistic regression model to study the effect of
multiple variables associated with the remission in
Grave’s disease. A p-value of less than 0.05 (level of
significance) was taken as significant.

RESULTS
In the analysis of 74 patients of Grave’s disease,
females were predominant (62.6%) with a mean age of
41 years. During the follow-up period of 18 months,
41.9% (n=31: males 12, females 19) of patients went
into remission, 44.5% (n=33: males 12, females 21)
never went into remission, while 13.6% (n=10: males 4,
females 6) went into relapse, thus patients with
treatment failure were 58.1% (n=43: males 16, females
27). Remission rate calculated was 41.9%. All patients
tolerated the oral anti-thyroid agents well and none of
the patients developed any side effects.
Table I and II show the clinical symptoms, remission and
relapse rates at different stages of follow-up. Table III
highlights different variables and their impact on
remission and treatment failure groups. No statistical
difference was observed in males and females in
remission and treatment failure groups. Univariate
analysis showed that the initial free T4 level was
significantly different (p < 0.05) in patients in remission
and treatment failure groups. Multivariate analysis
showed only initial free T4 level was found to be a
significant predictor of outcome. Positive antimicrosomal antibody patients (n=27) had higher
treatment failures (odds ratio: 2.55: 95%, CI 0.69 – 9:31)
compared to negative ones, although the difference was
not statistically significant (p = 0.13) on univariate and
multivariate analysis.
Table I: Symptoms in patients with Grave’s disease at different
stages of follow-up (n=74).
Symptoms
Palpitations
Fatigue
Sweating
Weight loss
Heat intolerance
Muscle cramps
Tachycardia
Warm moist skin

Initial
visit
3 months
42 (57%)
7 (9.5%)
32 (43.2%) 2 (2.7%)
21 (28.3%) 7 (9.5%)
64 (86.4%) 13 (17.5%)
37 (50%)
6 (8.1%)
4 (5.4%)
3 (4.1%)
43 (58%)
11 (14.8%)
9 (12.1%) 5 (6.7%)

Follow-up
6 months 12 months 18 months
4 (5.4%) 11 (14.8%) 6 (8.1%)
4 (5.4%) 11 (14.8%) 7 (9.5%)
1 (1.3%)
2 (2.7%)
0 (0%)
8 (10.8%) 15 (20.7%) 12 (16.2%)
3 (4.1%)
5 (6.7%)
0 (0%)
2 (2.7%)
5 (6.7%)
1 (1.3%)
9 (12.1%) 8 (10.8%) 7 (9.5%)
2 (2.7%)
2 (2.7%)
3 (4.1%)

Table II: Remission and relapse rates at different stages of the
follow-up.
Group
Patients in remission
Patients with replase

3 months
0%
-

Follow-up*
6 months
12 months 18 months
9 (12.2%)
22 (29.7%) 31 (41.9%)
3 (4.1%)
7 (9.5%)

* Percentages calculated from the total patients (n=74). At the end of 18 months, 41.9% of
patients were in remission, 9.5% relapsed making a total of 58.1% (n=43) patients with
treatment failure.
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Table III: Impact of different variables on remission and medical
treatment failure groups.
Variables
Number of patients
Gender
Males
Females
Age
Mean
Median
Mode
SD
Outcome in patients
< 40 years of age
(30/74 or 40%)
Outcome in patients
≥ 40 years
(43/74 or 58%)
Mean free T4 on
first visit
Mean dose of
Carbimazole
Clinically palpable
goitre
Positive antimicrososmal antibody
Positive Antithyroglobulin antibody
Presence of eye signs

Remission
group
31 (41.9%)

Treatment
failure group
43 (58.1%)

Odds ratio

p-value

-

-

12 (42.8%)
19 (41.3%)

16 (57.14%) 1.06 (0.41-2.75:
27 (58.6%)
95% CI)

0.543

43 years
44 years
30 years
12.0
11 (35.4%)

42 years
40 years
40 years
15.2
19 (44.1%)

-

0.698

0.69 (0.26-1.79:
95% CI)

0.305

20 (64.5%)

24 (55.8%)

2.3 ng/dl

4.7 ng/dl

-

0.025

31.6 mg

34.6 mg

-

0.340

25 (80%)

35 (81%)

0.583

10 (32.5%)

17 (39.5%)

12 (38.7%)

12 (27.9%)

8 (25.8%)

16 (37.2%)

1.05 (0.32-3.40:
95% CI)
2.55 (0.69-9:31:
95% CI)
0.58 (0.17-1.99:
95% CI)
1.76 (0.64-4.89:
95% CI)

0.134
0.291
0.197

Measurement of thyroid antibodies especially antimicrosomal and thyroid receptor antibodies (TRAb) are
essential in the diagnosis and prediction of disease
remission. Since, TRAb were not assayed in our centre
making comparison difficult in our case, we also have
not found any association of other thyroid antibodies
with disease remission or failure. Several previous
studies have explained the important relationship
between the high titre of these antibodies and disease
relapse.4-6,8,10,15,17 Unavailability of TRAb at the study
centre could be a possible reason for the lack of
association of thyroid antibodies with disease remission
in this study.
There are a few limitations seen in this study. These
include the short follow-up of 18 months and small
sample size due to lack of follow-up of some patients.

CI = Confidence interval; SD = Standard deviation.

DISCUSSION
The outcome of Graves’ disease treatment is variable,
and hence, identifying factors that could predict
treatment outcome before starting treatment will be
helpful for the patients. In our experience, the remission
of Graves’ disease in adults is not satisfactory, only
41.9% of patients experiencing successful remission
after cessation of medical therapy. This continues the
general trend for the decreasing likelihood of remission
reported in recent years.10-12 The finding that a high
percentage of patients eventually required radioiodine,
has later led us to offer radioiodine as an option for firstline therapy.
It is well noted that there was no difference in remission
or treatment failure rates in relation to gender, age, antimicrosomal/thyroglobulin antibodies, ophthalmopathy
and size of goiter. Several studies reported poor
prognosis after medical treatment and the influencing
factors on the remission rates include age, gender,
duration of symptoms before the start of treatment,
dosage of anti-thyroid drugs, goiter size, opthalmopathy,
severity of hyperthyroidism and presence of thyroid
antibodies.1,2,13,14 Although this study did not show age
as a predictor of treatment remission or failure, some
previous studies did mention that younger patients have
more treatment failures compared to older patients.1
The reason behind this finding could be the small
sample size and short duration of follow-up in the
presently reported patients.
692

High free T4 on initial presentation is associated with
higher treatment failures compared to low free T4 level.
This finding is in accordance with the studies from
Taiwan, Iran and Saudia.10,15-17 However, two of the
studies mentioned high free and total T3 instead of free
T4 as a predictor of treatment failure.10 Beside high free
T4 or T3, these studies also found that presence of large
goiter, past history of recurrence, and ophthalmology
suggest aggressive disease and the authors concluded
that alternate treatment options should be offered to
such patients.

CONCLUSION
The remission rates with oral anti-thyroid treament are
rather high. Patients who do not enter remission during
a period of 12-18 months of treatment, those who
develop replase, and those who have aggressive
disease on the initial presentation should be offered
alternate treatments options like radio-iodine ablation or
surgery. Physicians who hesitate to use radio-iodine as
a first-list therapy would be able to identify reliable
predictors of remission or relapse following oral antithyroid medication.
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